Amended Regulations

Regulation **.05** under **COMAR 14.01.01 General Provisions**

PDAB Meeting

November 16, 2026

PDAB Staff

MARYLAND
Prescription Drug Affordability Board

Register Comments Received

- Proposed Amended Regulations for COMAR 14.01.01.05 General Provisions, were posted in the September 4, 2026 version of the Maryland Register.
- Comments were due on October 5, 2026
- Comments were Received from the following entities (in combination with COMAR 14.01.04)
  - AbbVie
  - Boehringer Ingelheim USA Corporation
  - EACH/PIC Coalition
  - Healthcare Distribution Alliance
  - PhRMA
  - Regeneron Pharmaceuticals, Inc.
  - RxEconomics LLC
  - Value of Care Coalition

The written comment packet can be found here.

Purpose

- The regulations updated COMAR 14.01.01.05B(4) Public Comments - to provide for a comment period of at least 15 days when the Board requests comment by posting notice on its website (and no other regulatory provision applies)

Comments Received

- Some commenters expressed concern that 15 days was not adequate time to provide public comment.

PDAB Response: The 15 days was added into the regulations to provide a minimum amount of time to provide comments. Staff recommends no changes.

MARYLAND
Prescription Drug Affordability Board

comments.pdab@maryland.gov
pdab.maryland.gov